NORTH WEST LUNG CENTRE
Financial health, per its FY2025 accounts
The accounts state that the group's unrestricted reserves increased significantly to £129,919,251 following a £90.1 million gain on the revaluation of subsidiary shares. The trustees report that the continuous success and profitability of the subsidiary companies allows the charity to maintain unrestricted reserves at a level that can be re-assessed annually. The group generated a net incoming resource of £94.8 million, driven largely by investment gains rather than operational surplus.
What the accounts disclose
“It is the trustee’s policy to maintain sufficient reserves to enable the Charity to continue to support current research.” — page 7
“An honorarium of £6,000 was payable to trustee J Alcock in the year (2024 £Nil).” — page 27
“During the year, total dividends of £1,147,791 (2024 - £495,788) were paid to the directors of Medicines Evaluation Unit Limited and CRO Solutions Limited.” — page 36
“Professional fees of £nil (2024 - £7,236) were paid to Eversley Resolutions, a business operated by Mr J Alcock, a trustee of the charitable company.” — page 36
“During the year, total dividends of £1,147,791 (2024 - £495,788) were paid to the directors of Medicines Evaluation Unit Limited and CRO Solutions Limited.” — page 36
“Professional fees of £nil (2024 - £7,236) were paid to Eversley Resolutions, a business operated by Mr J Alcock, a trustee of the charitable company.” — page 36
“The Charity owned 84.92% of the share capital of Medicines Evaluation Unit Limited and 69.87% of the share capital of CRO Solutions Limited. Medicines Evaluation Unit Limited is a company principally engaged in evaluating medicines for the pharmaceuticals industry. CRO Solutions Limited is a clinical research organisation.” — page 8
Corporate structure
- Trading subsidiary: MEDICINES EVALUATION UNIT LIMITED Companies House 03779957
- Registered company of the charity Companies House 03936652
- Trading subsidiary: CRO SOLUTIONS LIMITED Companies House 09157193
Structured financials (annual return, FY ending 31/03/2025)
Trustees
- Alan Clarke
- Dr Huda Badri
- Dr Louise Ann Brown
- Malcolm Pike
- Professor Andrew Mark Jones
- Professor Ashley Woodcock
- Professor Clare Suzanne Murray
- Professor Jorgen Vestbo
- Professor Richard Booton
- Professor Sukh Dave Singh
- RICHARD BAILEY
- Timothy Graham Heatley
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 31/03/2025 | £20.9m | £16.0m |
| 31/03/2024 | £19.6m | £13.0m |
| 31/03/2023 | £19.0m | £15.1m |
| 31/03/2022 | £17.5m | £13.1m |
| 31/03/2021 | £15.9m | £12.5m |
Common questions
Is NORTH WEST LUNG CENTRE financially healthy?
The accounts state that the group's unrestricted reserves increased significantly to £129,919,251 following a £90.1 million gain on the revaluation of subsidiary shares. The trustees report that the continuous success and profitability of the subsidiary companies allows the charity to maintain unrestricted reserves at a level that can be re-assessed annually. The group generated a net incoming resource of £94.8 million, driven largely by investment gains rather than operational surplus. Its FY2025 accounts were audited by Mitchell Charlesworth (Audit) Limited.
Funders of similar charities
| Funder | Similar charities funded | Amount to them |
|---|---|---|
| GUY'S AND ST THOMAS' FOUNDATION | 1 | £872k |
| THE FIDELITY UK FOUNDATION | 1 | £419k |
| THE BRITISH DIABETIC ASSOCIATION | 1 | £184k |
| THE MICHAEL COWAN FOUNDATION | 1 | £150k |
| BRITISH HEART FOUNDATION | 1 | £100k |
| KUSUMA TRUST UK | 1 | £100k |
| THE HEALTH FOUNDATION | 1 | £100k |
| Arthritis UK | 1 | £97k |